Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;8(24):2371-3.
doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.

Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Stanley Zucker  1 , Jian Cao
Affiliations

Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Stanley Zucker et al. Cancer Biol Ther. 2009 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hypothetical function of mT1-mmP homodimer and heterodimer formation on proteolytic activity, cell migration and proliferation: The hemopexin (PeX) domain of mT1-mmP interacts with CD44 or an unknown protein (heterodimer) at the cell surface, which signals for cell migration through maPK, PI3K and rac pathways, possibly involving initial activation of receptor tyrosine kinases (rTK) and ras. maPK also signals to the nucleus leading to epithelial-mesenchymal transition (emT) by enhancing Twist-1 and Snail activation. enhanced activity of PI3K or Wnt signaling pathways leads to inhibition of GSK-3β, an important regulator for β-catenin and Snail. Inhibition of GSK-3β results in transcriptional downregulation of IκB, and hence enhances activity of nFκB and subsequent Snail expression. mT1-mmP also forms homodimers at the cell surface which is critically important for the enzymatic activity of mT1-mmP. Cleavage of cell-cell adherens junction molecule, e-cadherin by mT1-mmP leads to dissociation of the e-cadherin-β-catenin complex and results in β-catenin relocation. β-catenin relocation to nucleus serves as a transcription factor along with TCF to upregulate gene expression for cell proliferation. Positive and negative feedback loops involving mT1-mmP and e-cadherin maintain the aggressive character of emT cancer cells. mT1-mmP also cleaves prommP-2, most of extracellular matrix (eCm) components, growth factors, and cell surface receptors. Both proteolytic activity and non-proteolytic activity of mT1-mmP coordinate to promote cancer emT. other control mechanisms for mT1-mmP function in cells involve enzyme activation by furin in the trans Golgi network and an elaborate endocytic pathway (not shown).
See this image and copyright information in PMC

References

    1. Coussens L, Fingleton B, Matrisian L. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 2002;295:2387–92. - PubMed
    1. Overall CM, Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–39. - PubMed
    1. Zucker S, Cao J, Chen W-T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2001;19:6642–50. - PubMed
    1. Puerta DT, Cohen SM. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Topics Medicinal Chem. 2004:4. - PubMed
    1. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004;22:4631–38. - PubMed

Substances

LinkOut - more resources